Distribution of the phosphatidylinositol 3-kinase inhibitors pictilisib (GDC-0941) and GNE-317 in U87 and GS2 intracranial glioblastoma models - Assessment by matrix-assisted laser desorption ionization imaging

Drug Metabolism and Disposition

Volumn 42, Issue 7, 2014, Pages 1110-1116

  Salphati, Laurent ^a   Shahidi Latham, Sheerin ^a   Quiason, Cristine ^a   Barck, Kai ^a   Nishimura, Merry ^a   Alicke, Bruno ^a   Pang, Jodie ^a   Carano, Richard A ^a   Olivero, Alan G ^a   Phillips, Heidi S ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GNE 317; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; UNCLASSIFIED DRUG; [5 (6 (3 METHOXYOXETAN 3 YL) 7 METHYL 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDIN 2 YL)PYRIMIDIN 2 AMINE]; 2-(1H-INDAZOL-4-YL)-6-(4-METHANESULFONYLPIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YLTHIENO(3,2-D)PYRIMIDINE; ENZYME INHIBITOR; GNE-317; INDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PYRIMIDINE DERIVATIVE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTRAST ENHANCEMENT; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEMALE; GLIOBLASTOMA; GLIOMA CELL LINE; HISTOLOGY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; MASS SPECTROMETRY; METABOLISM; NUDE MOUSE; PROCEDURES;

ANIMALS; BRAIN NEOPLASMS; ENZYME INHIBITORS; FEMALE; GLIOBLASTOMA; HUMANS; INDAZOLES; MICE; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SULFONAMIDES; THIOPHENES; TISSUE DISTRIBUTION;

EID: 84903202263     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.057513     Document Type: Article

References (34)

1. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, and Bigner DD (2009) Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18:1061-1083.
2. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, and Elmquist WF (2013) Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 41:33-39.
3. Agarwal S, Sane R, Gallardo JL, Ohlfest JR, and Elmquist WF (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 334:147-155.
4. Agarwal S, Sane R, Oberoi R, Ohlfest JR, and Elmquist WF (2011) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13:e17.
5. Akhavan D, Cloughesy TF, and Mischel PS (2010) mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-oncol 12:882-889.
6. Bonavia R, Inda MM, Cavenee WK, and Furnari FB (2011) Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 71:4055-4060.
7. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, and Berman SH, et al.; TCGA Research Network (2013) The somatic genomic landscape of glioblastoma. Cell 155:462-477.
8. CBTRUS(2012) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2008, Central Brain Tumor Registry of the United States, Hillsdale, IL, www.cbtrus.org.
9. Chaurand P, Schwartz SA, Billheimer D, Xu BJ, Crecelius A, and Caprioli RM (2004) Integrating histology and imaging mass spectrometry. Anal Chem 76:1145-1155.
10. Chu C, Abbara C, Noël-Hudson MS, Thomas-Bourgneuf L, Gonin P, Farinotti R, and Bonhomme-Faivre L (2009) Disposition of everolimus in mdr1a-/1b- mice and after a pretreatment of lapatinib in Swiss mice. Biochem Pharmacol 77:1629-1634.
11. Clark MJ, Homer N, O'Connor BD, Chen Z, Eskin A, Lee H, Merriman B, and Nelson SF (2010) U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line. PLoS Genet 6:e1000832.
12. Cloughesy TF, Cavenee WK, and Mischel PS (2014) Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol 9:1-25.
13. Daniel WA, Wójcikowski J, and Pałucha A (2001) Intracellular distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. Br J Pharmacol 134:807-814.
14. de Vries NA, Beijnen JH, Boogerd W, and van Tellingen O (2006) Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother 6:1199-1209.
15. de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, and van Tellingen O (2012) Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs 30:443-449.
16. Fine RL, Chen J, Balmaceda C, Bruce JN, Huang M, Desai M, Sisti MB, McKhann GM, Goodman RR, and Bertino JS, Jr, et al. (2006) Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors. Clin Cancer Res 12:5770-5776.
17. Günther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, and Lamszus K (2008) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27:2897-2909.
18. Heffron TP, Salphati L, Alicke B, Cheong J, Dotson J, Edgar K, Goldsmith R, Gould SE, Lee LB, and Lesnick JD, et al. (2012) The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase a. J Med Chem 55:8007-8020.
19. Hofer S and Frei K (2007) Gefitinib concentrations in human glioblastoma tissue. J Neurooncol 82:175-176.
20. Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, and Grossman SA (2010) Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme. J Neurooncol 97:241-245.
21. Huang TT, Sarkaria SM, Cloughesy TF, and Mischel PS (2009) Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 6:500-512.
22. Huse JT and Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10:319-331.
23. Li F, Hsieh Y, Kang L, Sondey C, Lachowicz J, and Korfmacher WA (2009) MALDI-tandem mass spectrometry imaging of astemizole and its primary metabolite in rat brain sections. Bioanalysis 1:299-307.
24. Little SE, Popov S, Jury A, Bax DA, Doey L, Al-Sarraj S, Jurgensmeier JM, and Jones C (2012) Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity. Cancer Res 72:1614-1620.
25. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, and Gaasch JA, et al. (2010) Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16:5664-5678.
26. Network TCGAR; Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
27. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, and Soroceanu L, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173.
28. Pitz MW, Desai A, Grossman SA, and Blakeley JO (2011) Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 104:629-638.
29. Polli JW, Olson KL, Chism JP, John-Williams LS, Yeager RL, Woodard SM, Otto V, Castellino S, and Demby VE (2009) An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-3-chloro-4-[(3-fluorobenzyl)oxy]phenyl-6-[5-([2-(methylsulfonyl)ethyl] aminomethyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos 37:439-442.
30. Salphati L, Heffron TP, Alicke B, Nishimura M, Barck K, Carano RA, Cheong J, Edgar KA, Greve J, and Kharbanda S, et al. (2012) Targeting the PI3K pathway in the brain - efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier. Clin Cancer Res 18:6239-6248.
31. Salphati L, Lee LB, Pang J, Plise EG, and Zhang X (2010) Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 38:1422-1426.
32. Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, Gril B, Hua E, Palmieri D, and Polli JW, et al. (2012) Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 29:770-781.
33. Weber B, Winterdahl M, Memon A, Sorensen BS, Keiding S, Sorensen L, Nexo E, and Meldgaard P (2011) Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol 6:1287-1289.
34. Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, Krajewski S, Reed JC, von Deimling A, and Dichgans J (1998) Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 79:640-644.